Alignment Healthcare, Inc. — FY2023 Form 10-K
Reporting period: Year ended December 31, 2023. This is an annual filing; the supplied text does not provide a clear standalone fourth-quarter income statement or cash-flow figure. Comparisons below are FY2023 versus FY2022 unless noted. Amounts are in U.S. dollars.
Business context
Alignment operates Medicare Advantage plans and related care programs, primarily across California, North Carolina, Nevada, Arizona, Florida and Texas. It combines recurring CMS member payments with a technology-supported care model. Health Plan Membership was 119,200 at year-end 2023, up 21.1%; the company reported approximately 155,500 members effective January 1, 2024, across 53 markets. It also served approximately 8,900 people through ACO REACH as of that date.
Financial and operating performance
| Metric | FY2023 | FY2022 | Change / context |
|---|---|---|---|
| Revenue | $1,823.6 million | $1,434.2 million | Up 27.2% |
| Medical expenses | $1,622.6 million | $1,249.9 million | Up 29.8%, faster than revenue |
| Medical benefits ratio (MBR) | 88.5% | 86.5% | Up 2.0 percentage points |
| SG&A | $307.4 million | $295.6 million | Up 4.0%; up 12.5% excluding equity compensation |
| Loss from operations | $(127.8) million | $(128.6) million | Slightly narrower |
| Net loss | $(148.2) million | $(149.6) million | Net loss per share: $(0.79), versus $(0.83) |
| Adjusted gross profit | $208.8 million | $193.6 million | Up 7.9%; non-GAAP |
| Adjusted EBITDA | $(35.3) million | $(26.7) million | Loss widened; non-GAAP |
| Net cash used in operations | $(59.2) million | $(45.4) million | Cash use increased |
Earned premiums rose 25.8%, reflecting membership growth, higher revenue per member and increased ACO REACH revenue. Other revenue rose to $22.7 million, mainly from higher interest income. Management attributed medical-cost growth outpacing premiums to ACO REACH mix, richer benefits, less favorable prior-year claims development and higher unit costs. The company recorded $11.0 million of favorable prior-year claims development in FY2023.
At December 31, 2023, cash and cash equivalents were $202.9 million and current investments were $115.9 million; together these were $318.8 million of cash, cash equivalents and short-term investments. Total current assets were $483.5 million and current liabilities $263.0 million. Separately, cash, cash equivalents and restricted cash totaled $205.0 million. The company used $147.3 million in investing activities, primarily for Treasury purchases and capital expenditures, and reported $0.1 million of financing cash inflow.
Term-loan principal was $165.0 million ($161.8 million net of issuance costs). The variable interest rate ranged from 10.86% to 11.84% in 2023; the loan matures in September 2027. The company reported compliance with its financial covenants, including a $23.0 million minimum-liquidity requirement. Accumulated deficit was $880.3 million.
Material changes and notable items
- Revenue grew 27.2%, while medical expenses grew 29.8%; MBR increased to 88.5% from 86.5%.
- Operating and net losses narrowed modestly, but Adjusted EBITDA loss widened to $35.3 million from $26.7 million.
- Cash used in operations increased, and investing cash outflow rose substantially, largely reflecting purchases of short-term Treasury securities and higher capital expenditures.
- Interest expense increased 16.1% to $21.2 million, primarily due to a higher interest rate on debt.
- After year-end, Alignment entered a global-risk arrangement under which a third party controls care arrangements and bears related healthcare costs; Alignment expects to act as agent and record revenue net.
Outlook, risks and contingencies
- Management expects continued investment in growth, markets, technology, sales and marketing, and product offerings, with SG&A expected to rise in absolute dollars. It stated that liquid assets should fund operating and organic capital needs for at least the next 12 months, while cautioning that this is subject to risks and assumptions. The filing does not provide a clear numerical FY2024 revenue or earnings forecast.
- Management reported more than 90% of members were enrolled in plans rated 4 stars or higher for the 2024 rating year / 2025 payment year. Star-rating methodology changes, audits or weaker results could affect future payments, benefits and membership.
- CMS and HHS-OIG risk-adjustment audits are an important exposure. CMS’s 2023 rule changes the treatment of extrapolation and the fee-for-service adjuster; the company says these changes may materially increase repayments relative to prior expectations. Accurate medical coding and claims-reserve estimates are also significant risks.
- Healthcare costs, member mix, provider-contract renewals, competition, labor costs, Medicare funding and extensive regulatory requirements could pressure margins and cash flows. The business is geographically concentrated, with more than 94% of members in California as of December 31, 2023.
- The company reported $95.7 million of incurred-but-not-paid claims; estimating this liability was the auditor’s critical audit matter. The financial statements received an unqualified audit opinion, and management and the auditor concluded internal control over financial reporting was effective.
- A wage-and-hour class action had a tentative $913,000 settlement accrued at year-end, subject to court approval expected in the first or second quarter of 2024. Management said no pending lawsuit or claim was expected to have a material effect.
Important facts for investors to verify
- Whether membership growth and the post-year-end 155,500-member level translate into sustainable premium growth and improved MBR.
- Medical-cost trends, claims-reserve development and the outcome or potential financial impact of CMS risk-adjustment audits.
- Cash burn, capital spending and liquidity available at the operating subsidiaries, considering state restrictions on transfers to the parent.
- Variable-rate debt costs, covenant headroom and the ability to meet the 2027 maturity while funding growth.
- Future Star ratings, CMS payment and policy changes, and the economics of the new ACO global-risk arrangement.
- Settlement approval and final cost of the wage-and-hour litigation; also review dilution exposure from outstanding equity awards and potential share sales.